Mode
Text Size
Log in / Sign up
N/A N=105

AI-based Medical Device Validation for Early Melanoma Detection

Melanoma · Melanoma, Skin

Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Area Under the ROC Curve (AUC) for Melanoma Detection — 0.8482 Probability area (value from 0 to 1)

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
AI-based Computer-Aided Diagnosis (CAD) Software for Skin Lesion Analysis. (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
AI Labs Group S.L
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the ROC Curve (AUC) for Melanoma Detection
0.8482
PRIMARY
Accuracy for Melanoma Detection
0.81
PRIMARY
Sensitivity for Melanoma Detection
0.93
PRIMARY
Specificity for Melanoma Detection
0.80
SECONDARY
Top-1 Accuracy for Multiple ICD Categories
0.55
SECONDARY
Top-3 Accuracy for Multiple ICD Categories
0.7569
SECONDARY
Top-5 Accuracy for Multiple ICD Categories
0.8422
SECONDARY
Area Under the ROC Curve (AUC) for Malignancy Detection
0.90
SECONDARY
Sensitivity for Multiple Malignant Conditions Detection
0.81
SECONDARY
Specificity for Multiple Malignant Conditions Detection
0.86
SECONDARY
Predictive Values (PPV and NPV) for Malignancy
0.9247; 0.6789

Summary

The goal of this observational study is to learn if a computer-aided diagnosis (CAD) system can help identify skin cancer (cutaneous melanoma). The research focuses on adults who have skin spots that a doctor thinks might be cancerous. The main questions the study aims to answer are: Can the artificial intelligence (AI) tool accurately identify melanoma in skin images? How does the tool's accuracy compare to the clinical judgment of expert skin doctors (dermatologists)? Researchers will compare the results from the AI tool to the final diagnosis made by doctors or through a skin biopsy. A biopsy is a medical test where a small piece of skin is removed and checked in a lab. Participants will: Have their skin spots photographed using a special camera attached to a smartphone. Allow researchers to use their clinical data and biopsy results for the study. The study does not change the medical care participants receive. Doctors will continue to treat participants as they normally would. By testing this tool, researchers hope to find a way to detect skin cancer earlier and more accurately

Eligibility Criteria

Inclusion Criteria

  • Patients with skin lesions with suspected malignancy
  • Age over 18 years old
  • Patients who consent to participate in the study by signing the Informed Consent form

Exclusion Criteria

  • Patients under 18 years of age
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06221397). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search